stockrow
Saturday 7 November 2026
Export SGMOQ’s income statement to Excel — free account
Sangamo Therapeutics, Inc.
SGMOQ Healthcare Biotechnology
Sangamo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.6 million, down 31.6% from fiscal 2024.
- Revenue
- −77.6%
- EPS
- +42.9%
- Free cash flow
- +26.2%
Quarter to March 2026, against a year earlier
0.11
0.00
0.00%
Follow SGMOQ
Alert me
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.70 | 6.20 | 2.98 | 2.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.64) | (7.15) | (4.82) | (5.05) | |
P/B ratio |
7.08 | 32.65 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.57 | 6.11 | 3.15 | 2.82 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.57) | (2.64) | (1.28) | (1.08) | |
EV/FCF |
(3.30) | (2.63) | (1.27) | (1.08) | |
Quick Ratio |
0.81 | 0.62 | 0.50 | 0.54 | |
Current Ratio |
1.05 | 0.88 | 0.84 | 0.70 | |
Net Debt/EBITDA |
2.40 | 0.91 | 0.58 | 0.89 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.86 | 0.33 | 0.49 | 0.47 | |
Operating CF/Net income |
0.91 | 0.82 | 0.65 | 0.62 | |
Capex/Depreciation |
(0.01) | (0.03) | (0.01) | (0.01) | |
Research and Development Expense of Revenue |
147.95% | 4,843.72% | 220.96% | 1,842.58% | |
Selling, General and Administrative Expense of Revenue |
49.58% | 1,375.56% | 54.53% | 472.82% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
12.16% | 366.09% | 14.97% | 68.79% | |
Graham Net Nets |
(0.20) | (0.19) | (0.32) | (0.43) | |
Graham Number |
0.00 | 0.00 | 0.71 | 0.65 | |
Earnings Yield |
(51.85%) | (65.67%) | (104.76%) | (152.00%) | |
Free Cash Flow Yield |
(28.01%) | (37.53%) | (83.22%) | (92.87%) | |
Revenue per Share |
0.07 | 0.00 | 0.05 | 0.00 | |
Operating CF per Share |
(0.07) | (0.09) | (0.09) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.09) | (0.09) | (0.05) | |
Cash per Share |
0.15 | 0.10 | 0.07 | 0.07 | |
Shareholders Equity per Share |
0.08 | 0.02 | (0.05) | (0.05) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.08 | 0.02 | (0.05) | (0.05) | |
Free Cash Flow |
(18.18) | (28.56) | (24.42) | (19.29) | |
Working Capital |
2.23 | (6.05) | (6.64) | (16.02) | |
Capital Expenditures |
(0.02) | (0.06) | (0.01) | (0.01) | |
Net Current Asset Value |
(28.06) | (38.32) | (38.18) | (41.81) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.11 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.48 | 5.51 | 0.45 | 0.62 | |
Average Payables |
14.17 | 17.67 | 14.96 | 18.76 | |
Average Assets |
95.29 | 99.95 | 80.69 | 73.07 | |
Average Common Equity |
21.65 | 22.69 | 4.25 | (7.02) |
Columns are period end dates